Investor  Feasibility

Providing independent scientific due diligence and risk-adjusted technical assessments for life sciences investors.

Feasibility Service for Investors and Venture Capital in Biotech 

I provide a specialised feasibility assessment service for investors and venture‑capital groups evaluating biotech opportunities, including new drug candidates, clinical‑development programs, and advanced therapies (ATMPs). My approach integrates scientific, regulatory, and clinical‑development expertise to determine whether a project is viable, scalable, and capable of reaching regulatory approval and market access.

Value for Investors

My service helps investors and VC groups:

  • reduce scientific and regulatory uncertainty
  • identify hidden risks early
  • validate whether a project can realistically reach Phase I, Phase II, or MAA/BLA
  • understand the true cost and timeline of development
  • make informed investment decisions based on evidence, not assumptions

 Scientific Feasibility

Assessment of mechanism of action, biological plausibility, preclinical package robustness, translational strategy, and alignment with FIH/early‑phase requirements.

Review of clinical‑development strategy, comparator selection, endpoints, feasibility of patient recruitment, and alignment with oncology/ATMP guidelines.

Regulatory Feasibility

Evaluation of regulatory pathway (EMA/FDA), classification, CMC readiness, ATMP requirements, and gaps that may delay or block progression to clinical phases.

Analysis of CQAs, CPPs, process scalability, analytical strategy, and suitability for GMP manufacturing and future MAA/BLA submissions.